TB-500 (Thymosin Beta-4 fragment) is a synthetic peptide corresponding to the actin-binding domain of Thymosin Beta-4. Research protocols focus on tissue repair, angiogenesis, and anti-inflammatory effects.
Standard Research Dosage
Loading phase: 4–8 mg per week for 4–6 weeks (split into 2–3 injections). Maintenance phase: 2–4 mg per week. Subcutaneous or intramuscular administration.
Mechanism of Action
TB-500 binds G-actin monomers, modulating the actin cytoskeleton to promote cell migration. This mechanism underlies its effects on wound healing, angiogenesis, and cardiac repair observed in animal models.
BPC-157 + TB-500 Stack
The most commonly researched combination protocol: BPC-157 250–500 mcg/day + TB-500 2–4 mg/week. BPC-157 provides localized healing effects while TB-500 promotes systemic tissue repair and angiogenesis.